#Cannabis News: Isracann Biosciences (CSE: $IPOT.C) Aims to Develop Top Regional Cannabis Brands for Entry into EU Marketplace; @Isracann1

#Cannabis News: Isracann Biosciences (CSE: $IPOT.C) Aims to Develop Top Regional Cannabis Brands for Entry into EU Marketplace; @Isracann1

VANCOUVER BC, October 29, 2019 (Investorideas.com Newswire) - Isracann Biosciences Inc.  (CSE: IPOT) formerly Atlas Blockchain Group Inc. (CSE: AKE) (XFRA: A2PT0E) (OTC: ATLED) (the “Company”) is pleased to provide an operative overview and update regarding facility development activities in Israel.

Concurrent to and as part of the Company’s recent listing on the Canadian Securities Exchange it had satisfied the escrow release conditions for the net proceeds of its highly successful CAD$10.1 million financing efforts which bolstered an already healthy cash position.

This positions the company to immediately accelerate its planned Phase One Facility Design and Construction Services Program which consists of finalization of greenhouse facility design for cannabis cultivation and production in accordance with an existing technical specifications strategy; to rapidly advance greenhouse and related facility construction per the design; ensure adequate controls are in place against any diversion, theft and loss of cannabis products per regulatory standards; and ensure compliance with other protective security, health, and safety requirements in accordance with Israeli regulations.

Read this in full at https://www.investorideas.com/news/2019/cannabis/10292IsracannBiosciences.asp

To-date Isracann has entered into agreements for the development of medical cannabis cultivation projects with regional stakeholders holding preliminary breeding and cultivation licenses issued by the Israeli Ministry of Health. The regional stakeholder is required to renew these licenses each year and further bears the cost of electricity, property and related land taxes and are bound to working with Isracann to obtain the required licenses and to participate in the construction of the greenhouses.

Company CEO Darryl Jones notes, “We are very pleased to have achieved our very important initial milestone targets with the CSE listing of our ticker symbol “IPOT” and to confirm our accelerated investment plans in Israel are fully under way. We have lined up several key organizations and personnel and look forward to announcing a number of these key commercial agreements in the days and weeks ahead. We thank all our supporters for their belief in us, and in our belief that the Israeli agricultural sector will provide a huge leading role in positioning the Isracann brand as market leaders in the massive and underserved European cannabis marketplace.”

In related news, the Company welcomes the recent appointment of Irit Arbel, Ph.D. to its Board of Directors. Dr. Arbel brings significant senior multidisciplinary biopharma and governance experience to Isracann’s board. She serves as CEO, Co-Founder and Director of Neurocords Ltd., a company focused on developing new treatments for peripheral and spinal cord regeneration, and previously served as Director and President of Brainstorm Cell Therapeutics, and as Executive Vice President of Research and Development at Savicell Diagnostic, a biotechnology company. Dr. Arbel previously served as Chairperson of Real Aesthetics, a company specializing in cellulite ultrasound treatment, and BRH Medical, a developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early-stage technology-related companies. Previously, Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems, a biotechnology company, and prior to that as Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company. Dr. Arbel earned her Ph.D. in 1997 in Neurobiology, after performing research in the area of MS. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel’s Institute of Technology.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones

Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ATLED)

Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel's agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.  

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Contact

Investor Relations

Toll Free: +1 855.205.0226

Email: inquiries@isracann.com

Web:  www.isracann.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring CSE: IPOT is a paid for news release on Investorideas.com ($750) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Canadian #Defense Stocks in the News: Patriot One (TSX: $PAT.TO) (OTCQX: $PTOTF) Unveils New PATSCAN Mobile Concept at IACP Conference; @patriot1tech

Canadian #Defense Stocks in the News: Patriot One (TSX: $PAT.TO) (OTCQX: $PTOTF) Unveils New PATSCAN Mobile Concept at IACP Conference; @patriot1tech

TORONTO, ON – October 29, 2019 (Investorideas.com Newswire ) -- Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF)  (FRANKFURT: 0PL) (“Patriot One” or the “Company”), developer of the PATSCAN™ Multi-Sensor Covert Threat Detection Platform, will officially announce a new officer safety initiative at the 2019 International Association of Chiefs of Police (IACP) Conference in Chicago, Illinois at the McCormick Place Convention Center.

In addition to demonstrating the PATSCAN Platform at its booth #3950, the Company will introduce and demonstrate its new PATSCAN VRS-M (Mobile) concept. Thanks to its partnership with the University of North Dakota (UND), Patriot One will demonstrate the solution using a UND Police Department vehicle.  The PATSCAN VRS-M is focused on police officer safety and is designed for installation in police or other public safety vehicles.  The solution offers three alert solutions for police.  The first capability is threat detection with real-time alerts to responding law enforcement personnel and their dispatch centers, with a focus around preventing ambush attacks on officers working in and around their vehicles. The second capability of the PATSCAN VRS-M will be to alert of potential traffic collisions due to lane drift of passing vehicles, while officers are conducting traffic stops.  The third capability of the video recognition solution will be for BOLO/LPR alerts. The automatic BOLO/LPR system will search license plates visible to the camera and then alert the officer when an identification has been made.

Read this in full at https://www.investorideas.com/news/2019/defense/10291PatriotOne-PATSCAN-IACPConference.asp

“As a former police officer who has had fellow colleagues injured on the job, this is a very important initiative we’re proud to be involved with” shared Phil Lancaster, SVP of Business Development at Patriot One.  “Working through our Cisco Solutions Partner Program our video analytics team has expanded the PATSCAN VRS software beyond the detection of rifles, gun, knives, and fights. We’re now able to detect approaching threats and other common hazards facing police officers every day,” continued Dr. James Stewart, SVP Video Analytics for Patriot One and an active 15-year auxiliary police officer.

In addition, during the conference, Patriot One, Smarter Security and ReconaSense will be demonstrating the PATSCAN Platform’s integration with Smarter Security’s Door DetectivesⓇ access control solution.

New Website Launch

Patriot One will also unveil its new website, which offers greater focus, clarity and information around the PATSCAN Multi-Sensor Covert Threat Detection Platform, as well as insights into the Company’s role in shaping the physical security space in response to the distressing increase in active assailant tragedies around the globe.

“Our team has been working on the new website for several months, making sure that we clearly and concisely present our PATSCAN Platform in a way that our resellers and their end-clients can appreciate,” shared Martin Cronin, CEO and President of Patriot One. “In addition to having an interactive page that shows how each PATSCAN sensor may be deployed, we’ve also integrated our previously stand-alone PublicSecurity.today blog into the new site.  This is to provide our visitors with meaningful industry insights targeting relevant technical advances, trends and thought leadership in the sector.”

The new Patriot1tech.com offers a fresh clean look for the Company, which has begun rolling out the PATSCAN Platform. The website aims to showcase the Platform capabilities, along with new corporate and product category information including new videos that highlight many key benefits and features. The website also includes information on media coverage and upcoming industry events. The timing of the launch coincides with the 3-year anniversary of Patriot One’s official corporate launch, which was held during the 2016 International Association of Chief of Police (IACP) Conference in San Diego, CA.

To learn more about the overall PATSCAN Platform and the PATSCAN VRS-M Video Threat Detection Solution, visit Patriot One’s new website at www.patriot1tech.com. Attendees at the 2019 IACP Conference are invited to stop by Patriot One’s booth #3950 to speak with management and sales personnel.

Respectfully,

 “Martin Cronin”

Martin Cronin, CEO

About Patriot One Technologies Inc. (TSX:PAT) (OTCQX: PTOTF) (FRA: 0PL):

Patriot Ones' mission is to deliver innovative threat detection and counter-terrorism solutions for safer communities. Our PATSCAN™ Multi-Sensor Covert Threat Detection Platform provides a network of advanced sensor technologies with powerful next generation AI/machine learning software. The network can be covertly deployed from far perimeter to interiors across multiple weapons-restricted facilities. The PATSCAN™ platform identifies and reports threats wherever required; car park, building approach, employee & public entryways and inside the facilities. Each solution in the platform identifies weapons, related threats or disturbances for immediate security response. Our motto Deter, Detect and Defend is based on the belief that widespread use of the PATSCAN™ platform will act as an effective deterrent to diminish the epidemic of active threats around the globe. For more information, visit: www.patriot1tech.com or follow us on Twitter and Facebook.

For further information, please contact:

Patriot One Technologies Inquiries

info@patriot1tech.com

www.patriot1tech.com

Investor Relations

John Martin, Patriot One Technologies                      

+1 (888) 728-1332                                        

johnm@patriot1tech.com                                                                         

Media Contacts:

Scott Ledingham, Patriot One Technologies                        

+1-613-806-7135                                          

scott@prmedianow.com                                             

CAUTIONARY DISCLAIMER STATEMENT:

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to system sales, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects”,” believes”, and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include development and commercialization delays, counterparty default and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law.

Neither the Toronto Stock Exchange (TSX) nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring TSX: PAT is a paid for news release on Investorideas.com ($750) More disclaimer info: 

https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Get more Defense Stock Investor Ideas - news, articles, and stock directories

#BioPharma Snapshot; New Growth Strategies Continue for the Industry - (TSXV: $ICO.V) (OTCQB: $ICOTF) (NASDAQ: $ALXN) (NASDAQ: $BIIB) (NASDAQ: $ACHN) (NASDAQ: $PRVB)

#BioPharma Snapshot; New Growth Strategies Continue for the Industry - (TSXV: $ICO.V) (OTCQB: $ICOTF) (NASDAQ: $ALXN) (NASDAQ: $BIIB) (NASDAQ: $ACHN) (NASDAQ: $PRVB)

Point Roberts WA, Delta, BC – October 29, 2019 - Investorideas.com, a leading investor news resource covering pharmaceutical and biotech stocks releases a sector snapshot reporting on the growth of the global monoclonal antibody market and how this is affecting industry decisions moving forward.

Read this in full at https://www.investorideas.com/news/2019/biotech/10291BioPharma-GrowthStrategies.asp

Why is this a sector to pay attention to? According to recent industry reports,“ The Monoclonal Antibodies market worldwide is projected to grow by US$47.6 Billion, driven by a compounded growth of 6%.. Poised to reach over US$44.3 Billion by the year 2025, Inflammatory Disease will bring in healthy gains adding significant momentum to global growth.”

As this segment of bio/pharma grows in size and scale, we are seeing it become a more prominent focus for many companies in the industry. At present, the global Monoclonal Antibody Based Products market is chiefly driven by a number of outstanding firms and the major market players are beginning to execute different growth strategies including new product launches, strategic partnerships & collaborations, operational & geographical expansions, joint ventures, mergers & acquisitions and sales to grab a superior business position. Key players include Abbott Diagnostics, Inc., Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company and Eli Lilly and Company.

Is there room for smaller players?

iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) thinks so. The Company, which identifies existing development stage assets for use in underserved ocular and infectious diseases, recently announced several corporate developments related to their monoclonal antibody product, Bertilimumab.

iCo has been monitoring a current US court-mandated auction process, with respect to systemic uses of Bertilimumab, previously sublicensed to Immune Pharmaceuticals. On October 21, 2019, the bankruptcy court in New Jersey approved a sale order relating to the assignment of the sublicense of iCo's assets to Alexion Pharmaceuticals (NASDAQ: ALXN) . With respect to the court approved assignment to Alexion, iCo did not object and their rights as the sub-licensor will continue under the sublicense agreement if Alexion acquires the asset in accordance with terms submitted to the bankruptcy court. Further approval by Israeli courts will be required. The company expects in the coming weeks to comment on outcomes, a potential new partnership and next steps for this asset.

Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function.

Favorable results from pre-clinical assessments resulted in three clinical studies of Bertilimumab conducted in the EU (a total of 126 patients – healthy individuals, patients with a history of seasonal allergic rhinitis and individuals with a history of seasonal allergic conjunctivitis) provided evidence of good safety and tolerability of Bertilimumab when administered by the intravenous (IV) or intranasal route as well as topical application to the eye.

More recently, Bertilimumab has been investigated in two Phase 2 trials. The first trial targeted patients with a skin condition called bullous pemphigoid and revealed good safety and efficacy results. A second trial has been carried out in patients with an inflammatory bowel disease called ulcerative colitis. Results from this trial are still pending. A Phase 2 clinical trial for patients with vernal keratoconjunctivitis and/or atopic keratoconjunctivitis (involving cornea and conjunctiva) is in preparation. A number of other indications have also been considered.

Therapy with Bertilimumab could be useful in treatments of a number of diseases where steroids and immune-suppressants or other drugs may need to be prescribed chronically (a number of these diseases appear to be seasonal), often resulting in adverse reactions that may become serious over time.

Separately, iCo has also solicited bids from CROs for assistance with iCo's wholly-owned ocular Bertilimumab asset. Currently the company expects to engage the Food and Drug Administration regarding an additional Phase 2 study in ophthalmology, to be run by the Company and/or prospective partners.

Biogen Inc. (NASDAQ: BIIB) and Eisai, Co., Ltd. recently announced that, after consulting with the US FDA, Biogen plans to pursue regulatory approval for Aducanumab, an investigational treatment for early Alzheimer’s disease (AD). Aducanumab is a monoclonal antibody that is supposed to prevent or slow down neurodegeneration by removing toxic beta-amyloid plaques from the brain in the early stages of this condition.

The Phase 3 EMERGE Study met its primary endpoint showing a significant reduction in clinical decline, and Biogen believes that results from a subset of patients in the Phase 3 ENGAGE Study who received sufficient exposure to high dose Aducanumab support the findings from EMERGE. Patients who received Aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language. Patients also experienced benefits on activities of daily living including conducting personal finances, performing household chores such as cleaning, shopping, and doing laundry, and independently traveling out of the home. If approved, Aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes.

In the news, “Shares of Biogen surged significantly after it announced new data on Aducanumab in patients with early Alzheimer’s disease (AD). The company released results from a new analysis of a larger dataset of the discontinued ENGAGE and EMERGE phase III studies on Aducanumab in patients with early AD. This analysis was conducted in consultation with the FDA. Biogen and Japanese partner Eisai had discontinued ENGAGE and EMERGE studies, following a futility analysis. Nevertheless, the new data showed that Aducanumab reduced clinical decline of Alzheimer’s disease in such patients as measured by the pre-specified primary and secondary endpoints. Based on this data, the company plans to submit a biologics license application seeking approval of the drug to the FDA in early 2020. The company also reported better-than-expected results for the third quarter of 2019, driven by higher sales of key multiple sclerosis drugs and continued global launch of spinal muscular atrophy drug, Spinraza.”

Based on discussions with the FDA, the Company plans to file a Biologics License Application (BLA) in early 2020 and will continue dialogue with regulatory authorities in international markets including Europe and Japan. The BLA submission will include data from the Phase 1/1b studies as well as the complete set of data from the Phase 3 studies.

The Company aims to offer access to Aducanumab to eligible patients previously enrolled in the Phase 3 studies, the long-term extension study for the Phase 1b PRIME study, and the EVOLVE safety study. Biogen will work towards this goal with regulatory authorities and principal investigators with a sense of urgency.

Biogen isn’t the only company to surge on recent developments, as in recent news, “Shares of Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), rocketed 82% in premarket trading Wednesday (October 16th), after the biopharmaceutical company agreed to be acquired by Alexion Pharmaceuticals Inc. in a cash deal valued at $930 million. Under the terms of the deal, Alexion will pay $6.30 for each Achillion share outstanding, which is 73% above Tuesday's closing price of $3.65 and implies a market-capitalization of $880.05 million. The deal also includes potential for an additional payment for Achillion shares in the form of contingent value rights (CVRs) to be paid if certain clinical and regulatory milestones are achieved. The CVRs include $1 a share for U.S. Food and Drug Administration approval of Danicopan and $1 a share for ACH-5228 phase 3 initiation.”

Danicopan, Achillion's lead drug candidate has received breakthrough therapy designation for treatment in combination with a C5 monoclonal antibody for patients with a rare blood disorder, paroxysmal nocturnal hemoglobinuria (PNH).

Provention Bio, Inc. (NASDAQ: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, recently announced that the European Medicines Agency (EMA) has granted PRV-031 (Teplizumab) PRIority MEdicines (PRIME) designation for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease.

PRIME designation is awarded by the EMA to promising medicines that demonstrate the potential to address substantial unmet medical need based on clinical data.  The EMA considers PRIME designations a priority and provides them with special support, including enhanced interactions and dialogue, as well as a pathway for accelerated evaluation and review.

"We are very pleased the EMA recognizes the transformative potential of PRV-031 and has granted this groundbreaking therapy PRIME designation", said Ashleigh Palmerm CEO of Provention Bio.  "Following on the heels of Breakthrough Therapy Designation from the FDA in August, EMA PRIME further validates the rationale for PRV-031 to prevent or delay the onset of clinical T1D in at-risk subjects. We are committed to working closely with both regulatory agencies to bring PRV-031, as quickly as possible, to the many thousands of T1D at-risk individuals who currently have no options to prevent or delay this catastrophic disease."

PRV-031's PRIME designation was based on clinical data from the "At-Risk" Study conducted by TrialNet, which demonstrated that a single 14-day course of PRV-031 significantly delayed the onset of T1D, as compared to placebo, by a clinically-relevant median of at least 2 years in children and adults at high risk of developing clinical T1D. 

PRV-031, also known as Teplizumab, is an anti-CD3 monoclonal antibody (mAb), which is being developed for the interception and prevention of type 1 diabetes (T1D).  The candidate has been the subject of multiple clinical studies involving more than 1,000 subjects with more than 800 patients receiving PRV-031 in those studies. In previous studies of newly diagnosed patients, PRV-031 has consistently demonstrated the capability of preserving beta cell function and reducing the need for exogenous insulin usage.

Provention is currently evaluating PRV-031 in patients newly diagnosed with clinical T1D (the Phase 3 PROTECT Study).  Additional information on the clinical trial is available at www.clinicaltrials.gov.

As the Monoclonal Antibodies market worldwide is projected to grow by US$47.6 Billion, driven by a compounded growth of 6% with inflammatory disease displaying the potential to grow at over 6.4%, the shifting dynamics supporting this growth make it critical for businesses in this space to keep abreast of the changing pulse of the market.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining,  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring ICOTF is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com

800-665-0411

Get more Biotech Investor Ideas – news, articles and stock directories 

SinglePoint Inc. (OTCQB: $SING): #Hemp Cigarettes - What You Need to Know About One of the Fastest Growing Segments of Hemp; @_Singlepoint_

SinglePoint Inc. (OTCQB: $SING): #Hemp Cigarettes - What You Need to Know About One of the Fastest Growing Segments of Hemp; @_Singlepoint_

PHOENIX - October 29, 2019 (Investorideas.com Newswire) SinglePoint, Inc. (OTCQB:SING) has launched into the smokable hemp market. Newly released brand 1606 Original Hemp is gaining traction after much attention at the 2019 National Association of Convenience Stores launch. The company received orders on site at the show and gathered over 100 interested clients that collectively own over 15,000 locations. SinglePoint expects to make its first large sale in the near future and has shipped orders to a collective 250 locations.

Read this in full at https://www.investorideas.com/CO/SING/news/2019/10291HempCigarettes.asp

Hemp has been globally cultivated for thousands of years, but what is hemp and what makes the plant so special? Hemp is a strain that comes from the Cannabis Sativa plant species, it is an agricultural crop grown for seed and fiber. "Some of the earliest known uses of hemp began in China about 10,000 BCE, where it was used for making clothing, rope, and paper."

In today's world, hemp is becoming very popular. The use of hemp has evolved into diverse products such as lotions, oils, food, beverages, and cigarettes. Smokable hemp is a developing trend, but is it a good way to consume the cannabinoid? Here's what you need to know:

Hemp vs. Marijuana

Hemp and marijuana are both part of the cannabis family. However, hemp will not get you high unlike marijuana, which is known for its psychoactive effects. Marijuana has high levels of THC, containing anywhere from 5%-35% whereas hemp has less than 0.3% THC. Hemp contains high cannabidiol (CBD) content which is not psychoactive. Smoking hemp is a positive alternative to marijuana, "You get the same taste, the same psychological feeling of smoking a joint, but without the high."

Replacing Tobacco

Pure American Hemp cigarettes (link) are nicotine and tobacco free. Some research suggests that smoking hemp cigarettes could be a potential tool to replace tobacco and nicotine addictions. According to a Brightfield Group survey of more than 5,000 CBD users in the U.S.:

·        24% have used it to help quit smoking.

·        Quitters are often replacing cigarettes

·        with either smokable hemp or vaping.

·        41% of quitters have entirely replaced

·        tobacco with hemp CBD.

Google trends reveals over the last year that hemp was researched more often than tobacco and nicotine.

Initial Research

Initial research has shown CBDs ability to reduce cigarette consumption. Researchers at University College London conducted a study of 24 smokers. Each were given an inhaler with CBD or placebo. For one week they were to use the inhaler when they had the urge to smoke. Those with placebo had no difference in cigarettes smoked, those with the CBD inhaler significantly reduced the number of cigarettes smoked by 40%.

The Alternative Market

The Alternative Market has continued to grow drastically, 35%, from 2019 to 2018 while cigarettes stayed steady at 3.1%. With the addition of hemp cigarettes and the recent vape scare, many assume the alternative market will continue growing as people look for a "healthier for you" alternative to cigarettes.

The Future

BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024 while New York-based investment bank Cowen & Co, estimates that the market could pull in $15 billion by 2025. The smokable hemp market currently represents approximately 2% of the overall CBD market, but with a 250% growth from 2017 to 2018, Brightfield Group, a Chicago-based cannabis market research firm, identifies dried and smokable hemp flowers as one of the fastest-growing segments of the CBD market.

About SinglePoint, Inc.

SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base. Through SingleSeed, the company is providing products and services to the cannabis industry.

Connect on social media at:

https://www.facebook.com/SinglePointMobile

https://twitter.com/_SinglePoint

https://www.linkedin.com/company/singlepoint

For more information visit: www.SinglePoint.com

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Corporate Communication

SinglePoint Inc.
855-711-2009
investors@SinglePoint.com
SinglePoint.com

SinglePoint (SING) is a featured stock on Investorideas.com

More info on SING at Investorideas.com Visit: https://www.investorideas.com/CO/SING/

Get News Alerts on SinglePoint Inc. SING

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. For Disclosure purposes SinglePoint Inc (OTCQB: SING) is a paid  annual news and social media company on Investorideas.com.  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp and  https://www.investorideas.com/About/News/Clientspecifics.asp . Learn more about our prices for publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories